logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
G

Global Nash/Mash Council

Scholars31
Papers10
Citations0
Related Papers (10)
Publication Date
delete
Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD
errLiver International
IF5.2
err2026-05-07
err0
PREAI
errMei-Hsuan Lee; Maria Stepanova; Michael Estep; Yan-Ling You; Xia-Rong Liu; Leyla de Avila; Brian Lam; Ming-Lung Yu; Zobair M. Younossi
errShare
errSave
Global Structural Determinants of MASLD: Development-Stratified Pathways Linking Food Systems, Metabolic Risk, and Liver Outcomes
errJHEP Reports
IF7.5
err2026-05-04
err0
errOAAI
errJames M. Paik; Markos Kalligeros; Shira Zelber-Sagi; Annette Paik; Saleh A. Alqahtani; Zobair M. Younossi
errShare
errSave
Making metabolic dysfunction-associated steatotic liver disease medicines affordable: Lessons from hepatitis C
errAnnals of Hepatology
IF4.4
err2026-04-18
err0
errOAAI
errKhalid M. AlNaamani; Mohamed El-Kassas; Zobair M. Younossi
errShare
errSave
Lifespan approaches for the prevention and management of steatotic liver disease
errNature Reviews Gastroenterology & Hepatology
IF51
err2026-04-15
err0
PREAI
errShira Zelber-Sagi; Dana Ivancovsky-Wajcman; Carina Kugelmas; Ali A. Weinstein; Vincent Wai-Sun Wong; Laurent Castera; J. Bernadette Moore; Marialena Mouzaki; Kate Hallsworth; James M. Paik; Jeffrey B. Schwimmer; Lynn H. Gerber; Zobair M. Younossi
errShare
errSave
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
errALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
err2026-04-06
err0
PREAI
errNaim Alkhouri; Naga Chalasani; Zobair Younossi; Rohit Loomba; Meena Bansal; Jeffrey V. Lazarus; Sam E. Moussa; Rashmee Patil; Jörn M. Schattenberg; Samer Gawrieh; Mazen Noureddin
errShare
errSave
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review
errLiver International
IF5.2
err2026-03-28
err0
errOAAI
errHannes Hagström; Chris Hellmund; Jeffrey V. Lazarus; Riku Ota; Mary E. Rinella; Giada Sebastiani; Fotis Tefos; Zobair M. Younossi; Mazen Noureddin
errShare
errSave
Special Population
errClinics in Liver Disease
IF4.1
err2026-03-23
err0
PREAI
errWinston Dunn; Aleksander Krag; Patrick Kamath; Ashwani K. Singal
errShare
errSave
Self-Reported Cognitive Function in MASLD and MASH: A Post-Hoc Analysis of the MAESTRO Resmetirom Trials
errJournal of Clinical and Experimental Hepatology
IF3.2
err2026-03-05
err0
PREAI
errZobair M. Younossi; Fatema Nader; Dominic Labriola; Rebecca Taub; Andrei Racila; Linda Henry; Maria Stepanova
errShare
errSave
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa
errClinics in Liver Disease
IF4.1
err2026-03-05
err0
PREAI
errMohamed El-Kassas; C. Wendy Spearman; Manal El-Sayed; Zobair M. Younossi
errShare
errSave
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis
errHepatology Communications
IF4.6
err2026-02-26
err0
errOAAI
errYounossi, Zobair M.; Nader, Fatema; Labriola, Dominic; Taub, Rebecca; Racila, Andrei; Henry, Linda; Stepanova, Maria
errShare
errSave